Program

Thursday September 12, 2013

14.00-18.00  Registration Desk open
16.30-16.45  Welcome and Opening Remarks

16.45-18.00  Session 1: Regeneration: What It Is, How It Occurs, And Lessons From Other Organs

• Kaoru Sugimoto (California Institute of Technology, Pasadena, USA) “Dedifferentiation And Transdifferentiation”

• Tom Rando (Stanford University CA, USA) “Epigenetic mechanisms of stem cell aging and rejuvenation”

18.30-19.30  Welcome Cocktail

Friday September 13, 2013

08.30-10.15  Session 2: Renal Stem/Progenitor Cells Across Evolution

• Alan Davidson (University of Auckland, New Zealand) “Renal Regeneration In Zebrafish”

• Friedhelm Hildebrandt (Children’s Hospital, Boston, USA) “Centrosomal Roles for Tissue Dysplasia and Degeneration”

• Steven X. Hou (National Institute of Health, USA) “Renal Stem Cells In The Malpighian Tubules Of The Drosophila”

10.15-10.45  Coffee Break
10.45-12.00  Session 3: Renal Stem/Progenitor Cells During Kidney Development

- Andy McMahon (University of Southern California, USA)  "Transcriptional control of Nephron Progenitor programs"

- Frank Costantini (Columbia University Medical Center, New York, USA)  “Genetic and Cellular Basis of Ureteric Bud Branching Morphogenesis”

12.00-14.00  Lunch and Poster Session

14.00-15.45  Session 4: Embryonic Stem Cells And The Kidney

- Joseph Bonventre (Harvard Medical School, Boston, USA)  “Directed Differentiation Of Embryonic Stem Cells To Intermediate Mesoderm”

- Melissa Little (University of Queensland, Brisbane, Australia)  “Turning Different Types Of Stem Cells Into Kidney”

- Paul Goodyer – (McGill University, Montreal, Canada)  "Mechanisms Of Embryonic Progenitors Engraftment And Differentiation"

15.45-16.15  Coffee Break

16.15-18.00  Oral Presentations selected from abstracts

Saturday September 14, 2013

08.30-10.15  Session 5: Renal Stem/Progenitor Cells In Mammalian Kidney I

- Wenzheng Zhang (University of Texas Medical School, Houston, USA)  “Aqp2- Expressing Progenitor Cells In The Kidney”

- Benjamin Humphreys (Harvard Medical School, Boston, USA)  "Tubular Regeneration”

- Stuart Shankland (University of Washington, Seattle, USA)  “Cells Of Renin Lineage As Progenitors”
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.15-10.45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10.45-12.30</td>
<td><strong>Session 6: Renal Stem/Progenitor Cells In Mammalian Kidney II</strong></td>
</tr>
<tr>
<td></td>
<td>• Tobias Huber (University Hospital Freiburg, Freiburg, Germany) “New Insights in Glomerular Regeneration”</td>
</tr>
<tr>
<td></td>
<td>• Janos Peti-Peterdi (University of Southern California, Los Angeles, USA) “Imaging Glomerular Regeneration”</td>
</tr>
<tr>
<td></td>
<td>• Paula Romagnani (University of Florence, Florence, Italy) “Renal Progenitors and Kidney Regeneration in Human”</td>
</tr>
<tr>
<td>12.30-13.45</td>
<td>Lunch and Poster Session</td>
</tr>
<tr>
<td>13.45-15.45</td>
<td><strong>Session 7: Progenitors’ Driven Disorders</strong></td>
</tr>
<tr>
<td></td>
<td>• Agnes Fogo (Vanderbilt University Medical Center, Nashville, USA) “Progression And Regression Of Renal Disorders”</td>
</tr>
<tr>
<td></td>
<td>• Jochen Reiser (Rush University Medical Center, Illinois, USA) “Podocyte Injury and Repair – Novel Insights”</td>
</tr>
<tr>
<td></td>
<td>• Marcus Moeller (RWTH Aachen University, Aachen, Germany) “Crescentic Glomerulonephritis And Focal Segmental Glomerulosclerosis”</td>
</tr>
<tr>
<td></td>
<td>• Martin Johansson (Skåne University Hospital, Malmo, Sweden) “Renal Progenitors And Their Implications For Kidney Cancer”</td>
</tr>
<tr>
<td>15.45-16.15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16.15-18.00</td>
<td><strong>Session 8: Stem Cells In The Clinics: Results From Main Clinical Trials</strong></td>
</tr>
<tr>
<td></td>
<td>• Giuseppe Remuzzi (‘Mario Negri’ Institute, Bergamo, Italy ) “Stem Cell Therapy For Renal Transplantation: From Bedside To Bench And Return”</td>
</tr>
<tr>
<td></td>
<td>• Andreas Zeiher (Goethe University, Frankfurt, Germany) “Results From Clinical Trials About Stem Cell Therapy Of Heart Disorders”</td>
</tr>
</tbody>
</table>
• **Michele De Luca** (University of Modena and Reggio Emilia, Italy)  
  “Epithelial stem cells and regenerative medicine”

### Sunday September 15, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 9: Mechanisms Of Balance Among Regeneration And Repair</th>
</tr>
</thead>
</table>
| 8.30-10.45 | **Charles Alpers** (University of Washington, USA)  
  “Regeneration In Diabetic Nephropathy”  
  **Kai-Uwe Eckardt** (Friedrich-Alexander-University Erlangen, Nuremberg, Germany)  
  “Hypoxia and HIF in Tubulogenesis and Repair”  
  **Katalin Susztak** (Albert Einstein College of Medicine, New York, USA)  
  “Regenerative Pathways And Problems: Wnt, Notch, And The Response To Injury”  
  **Michael Goligorsky** (New York Medical College, Valhalla, New York, USA)  
  “Premature Senescence Of Epc And Tissue Fibrosis” |
| 10.45-11.15| Coffee Break |
| 11.15-13.00| Session 10: Strategies For Kidney Regeneration |
| 11.15-13.00| **Ton J. Rabelink** (Leiden University Medical Center, Leiden, The Netherlands)  
  “Endothelial Progenitor Cells In Kidney Injury And Repair”  
  **Sharon Ricardo** (Monash University, Victoria, Australia)  
  “Generation And Use Of Ips Cells For Kidney Disease”  
  **Ariela Benigni** (‘Mario Negri’ Institute, Bergamo, Italy)  
  “First Perspectives Of Kidney Engineering” |
| 13.00-13.15| Closing Remarks |
Speaker Biographies

CHARLES ALPERS

University of Washington, USA
September 15, 2013 (Session 9)

Dr. Alpers is Professor of Pathology with current research interests in experimental models of diabetic nephropathy and therapeutic interventions that promote regression of advanced disease. He also has a research program in experimental glomerulonephritis. He has been director of the clinical renal biopsy service at the University of Washington since 1986. He has co-organized the renal pathology course at the past four World Congresses of Nephrology.

ARIELA BEGNINI

Mario Negri Institute, Bergamo, Italy
September 15, 2013 (Session 10)

Ariela read Biological Science (Biol. Sci. D. Degree, University of Milan). She researched problems of anti-cancer and anti-thrombotic drugs in Milan and in Strasbourg before joining the Mario Negri Institute for Pharmacological Research in Bergamo, Italy, where she studied mediators of renal damage including the role of endothelin-1 in progressive renal injury (Ph.D. Degree, University of Maastricht). She is currently the Head of Department of Molecular Medicine and Scientific Secretary of Mario Negri Institute for Pharmacological Research of Bergamo.

She has contributed to more than 230 research publications. Her recent work has looked at therapies to halt renal disease progression or even induce regression of kidney lesions by multidrug approach with the interest to characterize cellular determinants of kidney repair after angiotensin II blockade.

She acted as Associate Editor of Kidney International, Journal of Nephrology and International Journal of Artificial Organs; currently she is Editor of Expert Opinion on Therapeutic Patents and PeerJ. She was consultant of WHO for a multicentre observational study on the evaluation of the predictive ability of angiogenic factors for Pre-eclampsia. For this latter study she has been appointed as Senior Fellow by the University of Oxford, Nuffield Department of Obstetrics & Gynaecology.

She has recently been named to take part to the Visiting Committee of AERES – Agence d’Évaluation de la Recherche et de l’Enseignement Supérieur – for the evaluation of scientists at the Hôpital Necker in Paris and she received the Merit Award of Bergamo City Hall for her contribution to science.
JOSEPH BONVENTRE
Harvard Medical School, Boston, USA
September 13, 2013 (Session 4)

Dr. Bonventre is the Samuel A. Levine Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at the Massachusetts Institute of Technology. He is Chief of the Renal Division and Chief of the Biomedical Engineering Division of the Brigham and Women's Hospital. Dr. Bonventre's research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. Dr. Bonventre is past-president of the American Society of Nephrology, founding director of the Kidney group of the Harvard Stem Cell Institute and has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering. He has been awarded the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology.

FRANK COSTANTINI
Columbia University Medical Center, New York, USA
September 13 2013 (Session 3)

Dr. Frank Costantini received a B.S from Yale College in 1974, and Ph.D in Developmental Biology from the California Institute of Technology in 1980. He was a postdoctoral fellow at University of Oxford from 1980 - 1982. Since 1982, he has been a professor in the Department of Genetics and Development at Columbia University.

ALAN DAVIDSON
University of Auckland, New Zealand
September 13, 2013 (Session 2)

Dr. Alan Davidson is an Associate Professor in the Department of Molecular Medicine and Pathology in the School of Medical Sciences at The University of Auckland. He received a B.Sc (Hons) and a Ph.D from The University of Auckland and did his Post-Doctoral training at Children’s Hospital/Harvard Medical School in Boston, USA. In 2005, Dr. Davidson started his own research programme in the Centre for Regenerative Medicine at the Massachusetts General Hospital/Harvard Medical School before being awarded the Rutherford Foundation Distinguished fellowship and returning to New Zealand in 2010.
MICHELE DELUCA

University of Modena and Reggio Emilia, Italy

September 14, 2013 (Session 8)

Michele De Luca is Full Professor of Biochemistry, University of Modena and Reggio Emilia and Director of the Centre for Regenerative Medicine S. Ferrari. He is a founding member of International Ocular Surface Society, member of numerous scientific societies and member of national and international committees. He is the author of more than 110 scientific publications in major international journals and author of 4 international patents. He was an invited lecturer in more than 140 international meetings and symposia. He was born in Savona, Italy, May, 17, 1956.

KAI-UWE ECKARDT

Friedrich-Alexander-University Erlangen-Nuremberg, Germany

September 15, 2013 (Session 9)

Kai-Uwe Eckardt is Professor of Medicine and Head of the Department of Nephrology and Hypertension at the University of Erlangen-Nuremberg, Germany. He attained an MD from the University of Münster in 1985 and obtained residency and fellowship training in pathology, physiology, internal medicine and nephrology at the Universities of Münster, Hannover, Zurich, Oxford and the Charité in Berlin. His major scientific interests lie in the molecular mechanisms and physiological/pathophysiological relevance of oxygen sensing, and the management of anemia.

He was chairman of a collaborative research center on kidney injury, founded by the German Research Foundation and principal investigator of a national CKD cohort study in Germany. Dr. Eckardt serves on the editorial boards of the Journal of the American Society of Nephrology, Kidney International, Nephrology, Dialysis and Transplantation and the Journal of Molecular Medicine. Since 2009 he is member of the ISN council and chair of the ISN Forefronts Committee. From 2008 until 2011 he served as co-chair of the global organization KDIGO (Kidney Disease: Improving Global Outcomes).

AGNES FOGO

Vanderbilt University Medical Center, Nashville, USA

September 14, 2013 (Session 7)

Dr. Agnes Fogo did her undergraduate education at the University of Oslo, Norway and the University of Tennessee in Chattanooga, followed by medical school at Vanderbilt University Medical School, where she also did her Pathology residency and fellowship training. Her research interest focuses on progression and potential regression of chronic kidney disease, and is funded by NIDDK. She has published numerous research articles and reviews, and has authored two
textbooks of renal pathology. She is currently the John L. Shapiro Professor of Pathology, and Professor of Medicine and Pediatrics, and Director, Renal Pathology/EM Laboratory at Vanderbilt University Medical Center.

MICHAEL S. GOLIGORSKY
New York Medical College, Valhalla, New York, USA
September 15, 2013 (Session 9)

Michael S Goligorsky, M.D., Ph.D., holds the Alvin I. Goodman Chair in Nephrology, and is Professor of Medicine, Pharmacology and Physiology, Academic Chief of Renal Division, and Director of Renal Research Institute at the New York Medical College. After completing residency and fellowship, Michael joined the faculty of the State University of New York at Stony Brook (1988). He became a Professor of Medicine and Physiology in 1997 and named an Honorary Professor at the University College London (1998). In 2002 he was recruited by the New York Medical College to inaugurate Renal Research Institute. In 1991, Michael was elected to the American Society of Clinical Investigations; in 2002 elected to the American Association of Physicians. MSG serves as an Associate Editor for *Am J Pathology, Am J Physiology: Cell*, and a Topic Editor for *Nephrology, Dialysis and Transplantation*. His research interests include: the mechanisms of endothelial dysfunction as a harbinger of atherosclerotic, diabetic, and hypertensive vascular damage; stress-induced premature senescence (SIPS) of endothelial cells and the role of lysosomal dysfunction in this process; mechanisms of functional incompetence of endothelial progenitor cells (EPC) in chronic kidney disease; mechanisms of Alarm Signalling by an ischemic organ; and proteomic analysis of the urine in kidney disease.

PAUL GOODYER
McGill University, Montreal, Canada
September 13, 2013 (Session 4)

Dr. Goodyer is a Professor of Pediatrics and Human Genetics at McGill University. He is a pediatric nephrologist at the Montreal Children's Hospital where he also directs a research laboratory which focuses on the molecular regulation of kidney development and the pathogenesis of hereditary renal disease. Specific current interests include stem cell therapy for cystinosis, the genetic basis of renal hypoplasia and the molecular pathogenesis of polycystic kidney disease and Wilms tumor.
FRIEDHELM HILDEBRANDT  
*Children’s Hospital, Boston, MA, USA*  
*September 13, 2013 (Session 2)*

Friedhelm Hildebrandt, M.D. is currently a Professor of Pediatrics at Harvard Medical School and Chief of the Division of Nephrology of Boston Children’s Hospital. Dr. Hildebrandt is also an Investigator of the Howard Hughes Medical Institute (HHMI).

Dr. Hildebrandt’s research work is concerned with the identification and functional characterization of recessive single-gene causes of kidney diseases in children. His group has identified over 20 novel kidney disease genes and delineated the related pathogenesis. His lab studies the function of newly identified disease genes in disease models of mice and zebrafish as well as in cell-based systems. His work was involved in the early development of efficient methods for gene identification by combining homozygosity mapping with total human exome resequencing. Recently, his lab discovered that DNA damage repair plays a role in the pathogenesis of ciliopathies (Chaki et al. Cell150:533-48, 2012; Zhou et al., Nat Genet 44:910-15; editorial p. 836-8).

The research work of his lab has been supported solely by peer-reviewed research grants, mostly from the NIH, the HHMI, the Doris Duke Charitable Foundation, the March of Dimes, the Thrasher Research Foundation, and formerly the German Research Foundation. He has published over 220 original articles, many of them in high-ranking journals.

STEVEN X. HOU  
*National Institute of Health, USA*  
*September 13, 2013 (Session 2)*

Not available at time of print.

TOBIAS HUBER  
*University Hospital Freiburg, Freiburg, Germany*  
*September 14, 2013 (Session 6)*

Tobias B. Huber is an Associate Professor of Medicine and Senior Attending Physician at the University Medical Center, Freiburg. Huber’s main research interests are in understanding the molecular mechanisms underlying glomerular disease. His team identified several key molecular mechanisms of podocyte biology and progressive glomerular disease. Specifically, his work identified signalling programs that regulate podocyte cell survival, endocytosis, cytoskeletal organization and polarity, providing novel insight of how podocytes contribute to glomerular diseases. The latest research of Huber’s team in Freiburg includes the
study of mTor-autophagy signalling networks in glomerular disease and kidney aging. Dr Huber is also the Coordinator and chair of NephAge, a collaborative systems biology program that is designed to identify and analyze the complex and dynamic interplay of factors that control glomerular disease. Tobias B. Huber received numerous awards including the ASN Young Investigator Award 2012.

**BENJAMIN HUMPHREYS**  
*Harvard Medical School, Boston, USA*  
*September 14, 2013 (Session 5)*

Dr. Humphreys is Director of the Harvard Stem Cell Institute Kidney Program where he is a Principal Faculty member. He is an Assistant Professor of Medicine at Harvard Medical School and directs the Laboratory of Translational Research in Kidney Repair. He received a bachelor's degree from Harvard College and MD and PhD degrees from Case Western Reserve University. He completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Nephrology at Brigham and Women's Hospital in Boston. The recipient of the National Kidney Foundation Young Investigator Award the American Society of Nephrology Gottschalk Research Scholar Award, he is also an Established Investigator of the American Heart Association. He has published 32 peer-reviewed original publications and 31 review articles or book chapters. His laboratory investigates kidney injury and repair with a focus on stem cell and regenerative medicine approaches to develop new therapies for patients with kidney disease.

**MARTIN JOHANNSON**  
*Skåne University Hospital, Malmo, Sweden*  
*September 14, 2013 (Session 7)*

Dr. Johansson is from the west coast of Sweden. He studied medicine at Lund University and performed his Ph.D studies at Gothenburg University. The subject of his dissertation was placental transport. He joined an internship in clinical pathology in Malmö where he is currently working as senior consultant specialized in renal pathology and as Associate Professor. His research focuses on the kidney, more specifically renal regeneration and renal cell carcinoma. Whenever he has time left he spends most of it with his wife and six children.

**MELISSA LITTLE**  
*University of Queensland, Brisbane, Australia*  
*September 13, 2013 (Session 4)*
Professor Melissa Little is a NHMRC Principal Research Fellow at the Institute for Molecular Bioscience, University of Queensland, Australia. Her research encompasses the molecular basis of kidney development, renal disease and repair. She is internationally recognised both for her work on the systems biology of kidney development but also her pioneering studies into potential regenerative therapies in the kidney.

**ANDY MCMAHON**
*University of Southern California, USA*
*September 13, 2013 (Session 3)*

Professor McMahon joined the University of Southern California in July 2012 after 19 years at Harvard College where he was a Chairman of the Department of Molecular and Cellular Biology and faculty member in the Department of Stem Cell and Regenerative Biology, a founding member of the Harvard Stem Cell Institute and the Frank B. Baird Jr., Professor of Science. Professor McMahon is now the Keck Provost Professor at the University of Southern California, and Chair of the Department of Stem Cell Biology and Regenerative Medicine and Director of the Eli and Edythe Broad-CIRM Center for Regenerative Medicine and Stem Cell Biology within the Keck School of Medicine of USC. Professor McMahon is an elected Fellow of Royal Society, the American Association for the Advancement of Science, the American Academy of Arts and Sciences, and an elected Associate Member of the European Molecular Biology Organization. The McMahon group’s research focuses on the regulatory processes that construct, maintain and repair mammalian organ systems with a principal focus on the central nervous system, skeleton and kidney.

**MARCUS J. MOELLER**
*RWTH Aachen University, Aachen, Germany*
*September 14, 2013 (Session 7)*

Professor Moeller has received a broad scientific training in various institutions, until he established a research group at the RWTH Aachen University in 2004. During this time, he created the transgenic technology that is now used worldwide to target podocytes or glomerular parietal epithelial cells (PECs) in vivo. Scientifically, he has established two major areas of interest:

1. Mechanisms in glomerular pathology (in particular FSGS and crescentic glomerulonephritis)
2. Glomerular filtration and the pathogenesis of proteinuria.

His work has received the highest awards by the RWTH Aachen University and by the German Society of Nephrology. He is giving invited lectures at the major nephrological conferences of the ASN, ERA/EDTA and the ISN. He serves as subject editor for the journal "Nephrology, Dialysis and Transplantation", and he is member of the editorial board of *Kidney International.*
Dr. Janos Peti-Peterdi, MD, PhD is a Professor of Physiology and Biophysics and Medicine at the University of Southern California. A native of Budapest, Hungary, he received his medical and PhD degrees from the Semmelweis University Medical School. Dr. Peti-Peterdi came to the United States in 1997 to do postdoctoral training in renal physiology at the University of Alabama at Birmingham, Department of Medicine, Division of Nephrology. In 2004, he joined the faculty at the USC Keck School of Medicine, where he received his tenure in 2007. Dr. Peti-Peterdi has an active research program funded by NIH, the American Heart and Diabetes Associations, focused on the (patho)physiological regulation of kidney function, body fluid and electrolyte homeostasis, maintenance of blood pressure, and the renin-angiotensin system. His laboratory utilizes state-of-the-art imaging techniques, including multiphoton fluorescence microscopy to study the function of the intact kidney in health and disease, including diabetes mellitus and hypertension.

Dr. Peti-Peterdi is a member of the American Physiological Society Renal Section, American and International Society of Nephrology, and the American Heart Association High Blood Pressure Research and Kidney Councils. He is board member of the Hungarian Kidney Foundation. He has been an Established Investigator of the American Heart Association, and was the recipient of the Carl W. Gottschalk Research Scholar Award from ASN and the Young Investigator Award from the APS Renal Section. Dr. Peti-Peterdi serves on the editorial board of the American Journal of Physiology Renal Physiology and regularly reviews grants for the NIH and the AHA. In addition to teaching and mentoring medical and graduate students and postdocs, Dr. Peti-Peterdi is the director of the Multi-photon Imaging Core at USC.

Ton Rabelink is professor of medicine at the University of Leiden. He is currently head of the department of Nephrology and Transplantation and is acting chairman of the department of medicine. He is also the chairman of the Research Institute of Cardiovascular Medicine of Leiden University Medical Center. His main interest has been vascular biology and in particular endothelial cell biology and its implications for renal function. He has published over 300 papers in this field.
TOM RANDO

Stanford University CA, USA

September 12, 2013 (Session 1)

Dr. Rando is Professor of Neurology and Neurological Sciences at Stanford University. He is the Director of the Glenn Laboratories for the Biology of Aging at Stanford and Director of the Center for Tissue Regeneration, Repair, and Restoration at the Palo Alto VA Medical Center. His research interests include basic stem cell biology and the biology of aging, and his laboratory focuses on basic research in these areas and translational research related to stem cell bioengineering and regenerative rehabilitation for acute and chronic tissue injuries.

JOCHEN REISER

Rush University Medical Center, Illinois, USA

September 14, 2013 (Session 7)

Jochen Reiser, MD, PhD is the chairperson of the department of internal medicine at Rush University Medical Center and the Ralph C. Brown, MD professor of internal medicine at Rush University.

Dr. Reiser is a world-renowned research leader in the field of proteinuric kidney disease. His groundbreaking discovery of the first circulating factor known to start the process leading to focal segmental glomerulosclerosis significantly advanced the research and treatment of this disease. Currently, Reiser has three NIH-funded grants in renal disease and biomedical research. He is a member of the American Society for Clinical Investigation (ASCI) and was most recently also elected to the American Clinical and Climatological Society (ACCA).

Reiser earned his medical degree and PhD (summa cum laude) at the Ruprecht Karls University of Heidelberg, Germany and served his residency in internal medicine at the Albert Einstein College of Medicine in New York. He completed his fellowship in nephrology at Massachusetts General Hospital and Brigham and Women’s Hospital at Harvard Medical School in Boston. Prior to coming to Rush in September of 2012, Dr. Reiser was a professor of medicine, anatomy and cell biology, vice chairman for research in the department of medicine, and chief of the division of nephrology and hypertension at University of Miami Leonard M. Miller School of Medicine. Before that, Dr. Reiser was an assistant professor at Harvard Medical School and the founding director of the program in glomerular disease at the Massachusetts General Hospital.

With his appointment to Rush, Dr. Reiser became the youngest chairperson of internal medicine at an academic medical center in the United States.
GIUSEPPE REMUZZI

Mario Negri Institute, Bergamo, Italy

September 14, 2013 (Session 8)

Professor of Nephrology, Director of the Department of Immunology and Clinical Transplantation and Department of Medicine of the Ospedali Riuniti di Bergamo, Head of the Division of Nephrology and Dialysis of the same hospital. Research Coordinator of the Negri Bergamo Laboratories of the “Mario Negri” Institute for Pharmacological Research devoted to the study of human renal disease and their corresponding animal models from the perspective of pathophysiology and therapeutic intervention. He (co-)authored more than 1150 scientific publications. Received the International Society of Nephrology (ISN) Jean Hamburger Award (2005), the John P. Peters Award (American Society of Nephrology (ASN) 2007) and the ISN AMGEN Award (2011). At the World Congress of Nephrology 2013, he assumed the presidency of ISN, for the period 2013-2015.

SHARON RICARDO

Monash University, Victoria, Australia

September 15, 2013 (Session 10)

Sharon completed her PhD at the University of Melbourne in 1994, studying cellular and molecular pathways leading to kidney disease. She continued this theme of research as a US Kidney Foundation Fellow pursuing postdoctoral studies (1994-2000) at Pennsylvania State University in the Division of Nephrology where she was promoted to Assistant Professor in 1998. After returning to Australia as a NHMRC Howard Florey Fellow, Sharon established a research group at Monash University that currently focuses on the development of new therapies for kidney regeneration through stem cells, immune modulation and/or growth factor therapies. In her role as Associate Dean (Postgraduate Research Degrees) at Monash University, Professor Sharon Ricardo provides leadership on all aspects of Higher Degree Research (HDR) training for the Faculty. She chairs the Faculty Research Degrees Committee, which has overall responsibility for recruitment, scholarship rankings, enrolment and progression. Sharon has published more than 65 papers and received many awards including the Kidney Health Australia Bootle Award; the Judy S. Finkelstein Award (Penn State University); and the Marrion Merrell Dow excellence in Renal Research Award (American Physiological Society). In addition, she is the first named inventor on US granted patents that have emerged from her translational research targeting the development of new therapies for promoting organ growth in premature and growth-restricted babies. Sharon is an Editor of the *Nephrology* journal and serves on the Scientific Program and Education Committee of the Australian and New Zealand Society of Nephrology. She is
actively involved in the promotion and education of science to the broader community by engaging with secondary school students, patient groups and philanthropic societies.

**PAOLA ROMAGNANI**  
*University of Florence, Florence, Italy*  
*September 14, 2013 (Session 6)*

Paola Romagnani was born in Florence, Italy, in 1970. She graduated at the School of Medicine and Surgery, University of Florence in 1995 and obtained her PhD in 2001. In 1999, she has won the Hoechst Marion Roussel Foundation Award as best young Italian scientist. From 2006 she is Associate Professor of Nephrology and from 2009 Chair of Nephrology and Director of the Specialty School of Nephrology of the University of Florence. From 2010, she is Head of the Nephrology and Dialysis Unit at the University Hospital Meyer, Florence. She has published 127 manuscripts in international peer-reviewed journals. Her studies received over 9000 citations, with an H-index of 51. In 2007, she has won the first Edition of the European Research Council Starting Grant Young Investigator Award. From 2008 to 2011 she coordinated a Cooperative European Project of the FP7 Program. From 2011 she is Ambassador of the European Commission for the Programme “Youth on the move”. From 2012 she is included in AcademiaNet (www.academianet.org), the database of outstanding international female scientists organized by Robert Bosch Stiftung’s foundation in collaboration with Nature.

**STUART SHANKLAND**  
*University of Washington, Seattle, USA*  
*September 14, 2013 (Session 5)*

Dr. Shankland is the Belding H. Scribner Professor of Medicine, and Head of the Division of Nephrology, University of Washington, Seattle. His research interests are glomerular diseases and diabetic nephropathy. He is a past Associate Editor of JASN, and has served on several editorial boards such as Kidney International.

**KAORU SUGIMOTO**  
*California Institute of Technology, Pasadena, USA*  
*September 12, 2013 (Session 1)*

Dr. Kaoru Sugimoto is a Senior Research Fellow in the Division of Biology at California Institute of Technology. Her research goal is to understand mechanisms of plant regeneration. After getting a PhD in animal developmental biology in the University of Tokyo, she moved to the field of plant biology and joined Elliot Meyerowitz’s lab in 2006. In her years of postdoctoral research, she has
especially focused on describing the cellular origin and the differentiation states of regenerating cells in Arabidopsis plant, and has reviewed various regeneration systems in plants and animals as a comparative study.

**KATALIN SUSZTAK**

*Albert Einstein College of Medicine, New York, USA*

*September 15, 2013 (Session 9)*

Katalin Susztak MD, PhD is currently an Associate Professor of Medicine at the Renal Electrolyte and Hypertension Division of the University of Pennsylvania Perelman School of Medicine. Dr. Susztak earned her doctorate (MD, PhD) degrees at Semmelweis University School Medicine, Budapest, Hungary in 1997 and she completed residency in Internal Medicine and clinical fellowship in nephrology at the Albert Einstein College of Medicine. She completed her post-doctoral work with Dr. Erwin Bottinger, where she initially worked on genomic studies of diabetic kidney disease and also defined the role of podocytes in diabetic nephropathy development.

Dr. Susztak is a nephrologist and physician-scientist. Work in her laboratory is aimed towards the understanding of renal fibrosis and chronic kidney disease development. She has performed translational research work to identify novel, genetic, genomic and epigenomic biomarkers of chronic renal disease. She has shown that an integrative analysis of epigenetic and genetic settings in diseased cells can provide a rational basis for more accurately modelling the critical biological pathways involved in mediating the progressive phenotype in individual patients. Her laboratory uses genetic approaches and mice as a model organism to test the role of candidate signalling molecules directly in vivo. Specifically, her work highlighted the role of the Notch and Wnt/beta-catenin pathway in chronic kidney disease development, renal epithelial cell homeostasis, renal stem or progenitor cell function and differentiation. Her recent results have revealed the role of embryonic programs in adult disease development causing alterations in renal epithelial cells and causing kidney fibrosis development. These studies have broad impact and clinical significance, since novel pharmaceuticals can be created around these principles.

The work in the laboratory of Dr. Susztak is supported by the National Institute of Health, the American Diabetes Association and Juvenile Diabetes Association. Dr. Susztak is an elected member of the American Society of Clinical Investigation. She was the recipient of the 2011 Young Investigator Award of the American Society of Nephrology and American Heart Association for her groundbreaking research on chronic kidney disease development.

**ANDREAS ZEIHER**

*Goethe University, Frankfurt, Germany*

*September 14, 2013 (Session 8)*

Not available at time of print.
WHENZHENG ZHANG

University of Texas Medical School, Houston, USA

September 14, 2013 (Session 5)

Dr. Zhang is an Associate Professor in the University of Texas Medical School at Houston. He received his Ph.D. from MD Anderson Cancer Center and postdoctoral training from Howard Hughes Medical Institute, Baylor College of Medicine. His research focuses mainly on epigenetic mechanism of Na+ and water homeostasis, with a special emphasis on histone H3 K79 methyltransferase Dot1l and the epithelial Na+ channel. He created several mutant mouse models including Dot1l conditional knockout mice. Recently, he began to study biomarkers and stem cells in kidney injury and repair.